PETERS WILLIAM J 4

What Happened William J. Peters, Amphastar Pharmaceuticals’ CFO, EVP & Treasurer and a director, was granted equity awards on March 9, 2026: 58,693 restricted stock units (RSUs) and a derivative award of 121,071 shares (reported as an option/derivative). Both awards were reported at $0.00 (they are grants). On March 10, 2026, 3,297 shares were withheld/disposed at $18.91 per share to satisfy tax withholding, generating about $62,346. The equity awards are not open‑market purchases; the withholding was a routine tax-related disposition.

Key Details

• Grants: 58,693 RSUs (reported 2026-03-09) and 121,071 derivative/option shares (reported 2026-03-09) — acquisition price $0.00 (awards).
• Tax withholding (disposition): 3,297 shares on 2026-03-10 at $18.91/share = $62,346.
• Vesting: RSUs vest in four equal annual installments beginning March 9, 2027 (Footnote F1). The option/derivative award vests in four equal annual installments beginning March 9, 2027 (Footnote F3).
• Withholding note: The 3,297 shares were withheld to satisfy the reporting person’s tax liability related to RSU vesting (Footnote F2) — a common administrative action, not an open‑market sale.
• Filing: Form 4 filed 2026-03-11 for transactions on 2026-03-09 and 2026-03-10; appears timely (within Form 4 reporting window).
• Shares owned after the transactions are not specified in the provided excerpt.

Context

• RSU grants vest over time; the reported awards do not reflect an immediate cash purchase and are intended as compensation retention.
• The tax‑withholding disposition is routine and typically executed by the company to cover withholding obligations when equity vests; it should not be read as a directional bet on the stock.
• The 121,071 derivative entry reflects an option/derivative grant (not an exercised option).